Free adult phone chat trials montreal
The primary differentiator between Lexaria's products and others on the market is the company's patented delivery technology for non-psychoactive cannabinoids.In addition to being cost effective, the company's Dehydra TECH™ proprietary technology has been proven in both the laboratory and market to enhance the performance of beneficial compounds in ingestible products in what regards smell, taste, action duration and bio-availability and absorption.
The warm weather stops right about at the border (unless it presents a passport). Anglophone Canadians all speak with a stereotyped West/Central Canadian English accent, putting "eh" at the end of questions or affirmations, and prominently raising the "ou" in aboot every word containing it.Merger and acquisition (M&A) activity in the cannabis industry is heating up, and market analysts point to several important factors contributing to increased activity.Profit is always a central issue, and as the founders of companies established years ago seek attractive exit strategies, new players are considering ways to enter the field in a profitable way.However, demand for alternative tobacco and nicotine products aimed at reducing the risks of smoking is also growing at a rapid pace.Lexaria's technology offers a safer, healthier alternative to traditional nicotine delivery systems by allowing the infusion of nicotine molecules with different edible food ingredients or in capsule formats (The rapid evolution of technology and its increasing application also serve as catalysts for M&A, as larger companies pursue opportunities that are positioned for current or near-term commercial availability.
Such expertise and assets developed by smaller brands could potentially turn them into attractive targets for M&A activity. (OTC: LXRP) (LXRP Profile) is one such potential target due to its proprietary technology for improved taste, rapidity and delivery of bioactive compounds, including cannabinoids. As prepares to legalize the recreational use of marijuana next summer, the push for M&A becomes even greater.
"This wide-ranging patent allowance from the USPTO exceeds our expectations.
This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world's first nicotine edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market," Lexaria CEO stated in the press release ( PIn).
This allows for lower overall dosing and higher efficacy, a plus for cannabis suppliers and consumers alike.
The technology works with all ingested forms of cannabinoids, making Lexaria an enabler rather than a competitor, and allowing the company to develop partnerships with various biotech companies for cannabinoid research and development.
Analysts note an increase in interest from Canadian companies that wish to cross the border to become a part of the U. In 2017, one of the oldest marijuana dispensaries in (